Purification, structure determination and synthesis of covalitoxin-II, a short insect-specific neurotoxic peptide from the venom of the Coremiocnemis validus (Singapore tarantula)  by Balaji, R.Ashok et al.
Puri¢cation, structure determination and synthesis of covalitoxin-II,
a short insect-speci¢c neurotoxic peptide from the venom of the
Coremiocnemis validus (Singapore tarantula)
R. Ashok Balajia, Toru Sasakib, P. Gopalakrishnakonea;*, Kazuki Satob,
R. Manjunatha Kinic, Boon-Huat Baya
aVenom and Toxin Research Programme, Department of Anatomy, Faculty of Medicine, National University of Singapore,
4 Medical Drive, Singapore 117597, Singapore
bMitsubishi Kasei Institute of Life Sciences, 11 Minamiooya, Machida, Tokyo, 194-8511, Japan
cBioscience Centre, Faculty of Science, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore
Received 28 April 2000
Edited by Pierre Jolles
Abstract Spider venoms contain toxins that specifically im-
mobilize and kill insects. We report the purification and
characterization of a new insect-specific toxin named covalitox-
in-II (Cvtx-II ; mass, 3406.24 þ 0.64), from Coremiocnemis
validus (Singapore tarantula) venom. The complete 31 amino
acid sequence of Cvtx-II has been determined and it shows less
than 40% identity with spider toxins. However, Cvtx-II has
conserved cystine motif analogous to other spider and g-
conotoxins. Cvtx-II was chemically synthesized and identified
with the native Cvtx-II. Synthetic Cvtx-II induced insect-specific
non-lethal excitatory activity when injected into crickets, but not
in cockroaches and mice. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Spiders are active predators and most of them have devel-
oped venoms to capture their prey. The diversity of spiders
and their venoms (not all spiders are venomous) have at-
tracted the attention of the scienti¢c community in their
search for insecticidal toxins [1^4] and neurotoxins [5,6].
Such toxins have potential as selective biochemical and/or
pharmacological tools [6^8] and as lead molecules in drug
discovery [9].
Only a small percentage of the 40 000 known spiders have
been well characterized. Among the best known of all spiders
are Theraphosidaes, commonly called ‘tarantulas’. We have
puri¢ed three new peptide toxins (named covalitoxin (Cvtx)-
I, -II and -III) from the venom gland extract of Coremiocne-
mis validus, a species of spider found in South East Asian
tropical forests. In this paper, we report the puri¢cation and
biochemical properties of Cvtx-II. Cvtx-II was puri¢ed by
reverse phase high-pressure liquid chromatography (HPLC),
its molecular mass and complete amino acid sequence were
determined by electrospray ionization mass spectrometry
(ESI/MS) and Edman degradation, respectively. The toxin
was chemically synthesized by 9-£uorenylmethoxycarbonyl
(Fmoc) chemistry. Cvtx-II is a non-lethal insect-speci¢c neu-
rotoxic peptide. The toxin’s structural similarities with other
short spider toxins suggest that modulation of ion channel(s)
could be responsible for its action.
2. Materials and methods
2.1. Materials
Live tarantulas (C. validus) were from our collection maintained at
the Laboratory of the Venom and Toxin Research Programme, Fac-
ulty of Medicine, National University of Singapore. A reverse phase
HPLC column (Sephasil C18; 2.1 mmU100 mm) was obtained from
Pharmacia Biotech (Uppsala, Sweden). Reagents for N-terminal se-
quencing were from Applied Biosystems (Foster City, CA, USA). The
chromatographic solvent acetonitrile (ACN) was purchased from
Fisher Scienti¢c (Fair Lawn, NJ, USA), 4-vinylpyridine and tri£uoro-
acetic acid (TFA) were from Fluka Chemika-Biochemika (Buchs,
Switzerland). All other chemicals used were of analytical grade and
purchased from Sigma Chemical Company (St. Louis, MO, USA).
Sterile, non-pyrogen 0.9% NaCl injection B.P. was from B/Braun,
Melsungen AG (Malaysia). Fmoc-Tyr(tBu)-OPfp was purchased
from Novabiochem (Tokyo, Japan) and H-Lys(Boc)-OH from Koku-
san Chemicals Ltd. Fmoc-amino acids, Fmoc-Pro-resin and other
reagents used on the peptide synthesizer were obtained from Perkin-
Elmer Applied Biosystems Japan (Chiba, Japan).
2.2. Preparation and extraction of venom
The venom glands were dissected from cold anaesthetized spiders
and carefully separated from the muscle tissue and exoskeleton. The
venom gland extract was prepared by crushing 20 glands using a glass
rod into 2 ml of 0.9% normal saline. This was stored at 315‡C.
2.3. HPLC puri¢cation
The venom gland extract was cleared of tissue debris by centrifu-
gation at 14 000 rpm for 10 min. The supernatant was then applied
onto a reverse phase HPLC column Sephasil C18 (2.1 mmU100 mm)
equilibrated with 0.1% TFA using a Smart System (Pharmacia).
Bound peptides were eluted using a linear gradient of ACN. The
£ow rate used was 200 Wl/min. Elution of peptides was monitored
at 215 nm.
2.4. Electrospray mass spectrometry
Molecular masses of peptides were determined by ESI/MS on a
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Perkin-Elmer Sciex API III triple quadrupole instrument equipped
with a ionspray interface (Sciex, Thornton, Canada). The ionspray
voltage was 4600 V, the ring voltage 350 V and the ori¢ce voltage
45 V. A Shimadzu series LC10-AD quaternary pump was used for
solvent delivery. The sample was infused into the mass spectrometer
by £ow injection at 50 Wl/min.
2.5. Reduction and pyridylethylation of the peptide
The peptide was dissolved in 100 Wl of the denaturant bu¡er (6.0 M
guanidine hydrochloride, 0.13 M Tris, 1 mM EDTA, pH 8.0) con-
taining 0.07 M L-mercaptoethanol. The mixture was incubated at
37‡C for 2 h under nitrogen. Subsequently, 1.5-fold molar excess
(over sulfhydryl groups) of 4-vinylpyridine was added and incubated
at room temperature under nitrogen. The samples were then immedi-
ately desalted on the Sephasil C18 column (2.1 mmU100 mm).
2.6. Amino acid sequencing by automated Edman degradation
Amino acid sequencing was carried out by automated Edman deg-
radation using an Applied Biosystems 494 pulsed-liquid-phase se-
quencer. Phenylthiohydantoin (PTH) amino acids were identi¢ed us-
ing on-line reverse phase HPLC on a PTH-C18 column on an Applied
Biosystems 140C analyzer.
2.7. Chemical synthesis of the peptide toxin
A linear precursor of Cvtx-II was synthesized by solid phase meth-
odology with Fmoc chemistry on a Perkin-Elmer Applied Biosystems
model 433A peptide synthesizer. To prevent formation of diketopiper-
azine, protected dipeptide Fmoc-Tyr(tBu)-Lys(Boc)-OH was coupled
with Pro-resin in the ¢rst step. Fmoc-Tyr(tBu)-Lys(Boc)-OH was syn-
thesized from Fmoc-Tyr(tBu)-OPfp and H-Lys(Boc)-OH in a liquid
phase. Six cysteines were protected by trityl groups. All protective
groups were removed during cleavage from the resin using 82.5%
TFA containing 5% water, 2.5% ethanedithiol, 7.5% phenol and 5%
thioanisole. The peptide was recovered as a precipitate by the addition
of ether, collected on a glass ¢lter and extracted with 2 M acetic acid.
The extract was diluted to a ¢nal peptide concentration of 0.05 mM in
1 M ammonium acetate (pH 7.9) containing 0.5 mM oxidized gluta-
thione, 5 mM reduced glutathione and 1 mM EDTA, and the resul-
tant solution was stirred at 4‡C for 48 h [10^14]. After acidi¢cation of
the mixture, the oxidized peptide was desalted and concentrated on an
octadecylsilane (ODS) column with a medium pressure pump. The
peptide mixture was subjected to gel ¢ltration on a Sephadex G-50F
(column: 5 cmU100 cm, solvent: 30% acetic acid) to obtain folded
monomer followed by ion exchange chromatography on a CM-cellu-
lose CM52 column (1.8 cmU20 cm). The CM52 column was equili-
brated with 0.01 M ammonium acetate (pH 4.6) and the peptide was
eluted using a linear gradient of the eluting bu¡er, 0.4 M ammonium
acetate, pH 6.5. Finally, Cvtx-II was puri¢ed by preparative reverse
phase HPLC (Shimadzu LC-8A system) using an ODS column (20
mmU250 mm). The molecular mass and homogeneity of the peptide
were determined by using matrix-assisted laser desorption/ionization
time-of-£ight mass spectrometry (MALDI-TOF-MS) on a PerSeptive
Biosystems Voyager Linear DE mass spectrometer using K-cyano-4-
hydroxycinnamic acid as a matrix. To determine whether the peptide
was folded similar to the native toxin, it was co-injected with native
Cvtx-II onto an analytical ODS column (4.6 mmU250 mm) using
Shimadzu LC-6A HPLC system. To ensure proper folding, the native
and synthetic Cvtx-II were co-eluted using either a shallow linear
gradient (5^30% ACN with aqueous 0.1% TFA) or isocratic (16%
ACN with aqueous 0.1% TFA) elution conditions.
2.8. Biological assays
The toxicity of Cvtx-II was determined using the following bioas-
says. Synthetic Cvtx-II was injected into unsexed crickets (Gryllotalpa
hexadactyla), German cockroaches (Blattella germanica, n = 8, 0.3^0.8
g, intrathoracical injection) and 2 week old Swiss mice (n = 4, 6^8 g
body weight, intracerebral injection). The sample was dissolved in
0.9% normal saline. The insects were restrained by their wings and
Cvtx-II was injected (20^50 Wl volume, 0.1^1.0 Wmol/g insect) into
their thoracic body cavity. The injections were performed with a
¢ne capillary Hamilton microsyringe. Mice were injected intracere-
brally with 20 Wl of the samples (n = 4, maximal concentration 0.1
Wmol/mouse). The animals were observed at regular intervals up to
6 h post-injection for any behavioral changes or death. Control ani-
mals were injected with 20 Wl of 0.9% normal saline.
3. Results and discussion
Spiders use their venoms to incapacitate their prey. The well
studied components in spider venom have been broadly clas-
si¢ed into two types: polyamines [15] and polypeptide com-
ponents [16]. Most research on spider toxins has focused on
the analysis of neurotoxic components, especially neurotoxic
polypeptides [17^20]. Toxins from the venoms of scorpions,
spiders and wasps can provide novel molecules for the design
and development of new insecticides.
Crude venom from C. validus was fractionated by reverse
phase chromatography on a Sephasil C18 column (Fig. 1A).
Protein elution was monitored at 215 nm and 25 peaks were
observed on the chromatogram. All peaks were tested for
their purity by ESI/MS. Three peaks were homogeneous and
were named Cvtx-I, -II and -III (with the Roman numericals
indicating their order of elution). Cvtx-II was eluted as a
sharp peak between 30 and 40 min interval at a gradient
less than 30% of solvent B (80% ACN in 0.1% TFA) (Fig.
1A). The mass spectrum of Cvtx-II showed three multiple-
charged ions with m/z = 852.73 (M4), 1136.43 (M3) and
Fig. 1. Puri¢cation, homogeneity and mass spectrum of Cvtx-II. A:
HPLC chromatography of C. validus venom on Sephasil C18 col-
umn (2.1 mmU100 mm). The column was equilibrated and washed
with 0.1% TFA and bound peptides were eluted using a linear gra-
dient of 0^60% for 45 min and 60^100% for 20 min ACN in aque-
ous 0.1% TFA at a £ow rate of 200 Wl/min. Elution of peptides was
monitored at 215 nm. B: Determination of homogeneity and molec-
ular mass of Cvtx-II by ESI/MS. Ionspray voltage = 4600 V; ori¢ce
voltage = 45 V; ring voltage = 350 V; inset: reconstructed mass spec-
trum of the peptide.
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1703.81 (M2) (Fig. 1B). The deconvoluted mass spectrum
(Fig. 1B, inset) indicated that it has a molecular mass of
3406.24 þ 0.64.
The amino acid sequence of native Cvtx-II was determined
end to end by automated Edman degradation. All positions
were unequivocally assigned except for positions 2, 9, 15, 16,
21 and 28, which showed no new peak. The peptide was
reduced, pyridylethylated and resequenced to determine the
positions of cysteine residues. Pyridylethyl-cysteines were
identi¢ed at each of the previously unidenti¢ed positions.
The complete primary amino acid sequence of Cvtx-II was
determined as ACSRAGENCYKSGRCCDGLYCKAYVVT-
CYKP. Cvtx-II has 31 residues including six cysteine residues
at position 2, 9, 15, 16, 21 and 28 forming three disulphide
bonds. The calculated molecular mass (3406.91) of Cvtx-II
matched the observed molecular mass (3406.24 þ 0.64), indi-
cating the presence of a free carboxyl-terminal. The peptide
has an almost equal distribution of hydrophilic (35.5%), hy-
drophobic (32.25%) and neutral (32.25%) amino acids. A
BLAST search [21] of the protein sequence database showed
low homology with two peptides, viz. spider peptide PLTX-II
(44 amino acids, presynaptic calcium channel blocker from
Plectreurys tristis ; 37% identity; 47% homology) and cono-
toxin MrVIB (31 amino acids, sodium channel blocker from
Conus marmoreus ; 40% identity; 47% homology). The cystine
motif of Cvtx-II is analogous to other spider toxins (Fig. 2)
and ‘g-toxins’ isolated from Conus venom, which block volt-
age-activated calcium channels [22,34^48]. Among these fam-
ilies of toxins, the disulphide bonding pattern is well con-
served (C1^C4, C2^C5 and C3^C6) [6,22,23]. Moreover,
these families share a common structural motif, viz. antipar-
allel L-sheet structure comprising three L-strands and £exible
loops, and the structure is stabilized by the cystine knot,
which forms the molecular nucleus [24]. However, despite
possessing this common structure, the members of this family
exhibit distinctly diverse and speci¢c biological e¡ects by tar-
geting a variety of ionic channels (Fig. 2). The di¡erence in
intercysteine loop structures appears to distinguish the a⁄nity
for di¡erent target proteins. In spider toxins including Cvtx-
II, conserved basic residues located close to the hydrophobic
C-terminus form a positively charged surface. This charged
surface is responsible for ion channel interaction in some spi-
der toxins [16].
Due to the scarcity of C. validus venom and very low yield
of Cvtx-II during puri¢cation, larger amounts of Cvtx-II
needed for activity studies were chemically synthesized. A lin-
ear precursor of Cvtx-II was synthesized by solid phase meth-
odology with Fmoc chemistry. A peptide lacking C-terminal
Lys-Pro was a dominant product when Pro-preloaded 4-hy-
droxymethyl-phenoxy-methyl-copolystyrene^1% divinylben-
zene resin was used, indicating formation of diketopiperazine.
The application of 2-chlorotrityl resin was also ine¡ective,
causing formation of many truncated peptides. Finally, the
linear precursor was successfully obtained by use of a pro-
tected dipeptide (Fmoc-Tyr(tBu)-Lys(Boc)-OH) in the ¢rst
coupling step. After oxidative folding reaction (Fig. 3A), syn-
thetic Cvtx-II was puri¢ed by gel ¢ltration, anion exchange
and reverse phase HPLC. Its identity with native Cvtx-II was
veri¢ed by MALDI-TOF-MS analysis. Its mass was deter-
mined as 3407.86 (MH). Co-elution of the synthetic and
native Cvtx-II from an ODS column using both gradient
(Fig. 3B) and isocratic conditions (data not shown) revealed
that the synthetic Cvtx-II has the same three-dimensional
structure as the native Cvtx-II.
Fig. 2. The primary sequence identities of Cvtx-II with other spider toxins. The amino acid sequences are aligned with their cysteine residues
for comparison; to maximize identity, the deletions (-) are included in the sequence. % I is percentage identity of Cvtx-II with other spider tox-
ins.
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The synthetic Cvtx-II was used for the characterization of
biological activity on crickets, cockroaches and young Swiss
mice. No visible symptoms or behavioral changes were ob-
served after Cvtx-II was injected in Dictyoptera German cock-
roaches (maximal concentration 0.3 Wmol/g) or Swiss mice
(maximal concentration 0.1 Wmol/mice). However, injection
of the peptide into crickets induced excitatory behavioral
symptoms such as quivering, jerking and hyperextension of
the legs. Rapid movement of antenna, mandibles and maxillae
with abdominal contraction and frequent body arching were
observed. This was accompanied by loss of righting re£ex
possibly due to limb weakness. Locomotion was greatly re-
duced in peptide-injected crickets as compared to the control
insects (crickets injected with normal saline). Gradual body
tilting to one side was observed within 10^15 min of injection.
Escape re£exes on application of cercal stimuli were either
weak or could not be elicited, indicating paralysis. The dose
required to immobilize or inactivate 50% of insect (ID50) was
0.2 Wmol/g (0.16^0.33 Wmol/g with 95% ¢ducial con¢dence
limits calculated using Probit analysis of data from eight
groups of at least four animals). The immobilizing e¡ect
lasted for 40^60 min with a gradual recovery of normal pos-
ture and activity.
The excitatory symptoms induced by Cvtx-II suggest that it
is a species-speci¢c anti-insect toxin which is analogous to
other anti-insect spider toxins [1] and scorpion toxins [25^
28]. Excitatory toxins are only active on insects and induce
immediate and reversible spastic^contractive paralysis
through sustained repetitive ¢ring as observed in locust neuro-
muscular preparation [29]. At the molecular level, the excito-
toxins retard insect sodium channel inactivation [30]. In light
of similarities in biological action with other excitotoxins, we
believe that insect ion channel protein could be the target of
Cvtx-II. Insect-selective excitatory toxins are valuable tools
for the study of the pharmacology of ion channels present
in insects and the design of insect-selective biopesticides
[31,32].
Understanding the natural predatory behavior of arthro-
pods will provide a better perspective of the biological signi¢-
cance of arthropod venom. In most cases of spider predation,
the prey is not eaten immediately after capture, but wrapped
in a ball of silk. Most tropical spider species possibly have
insect-speci¢c non-lethal/reversible neurotoxic components,
which could play a bene¢cial role in preventing the captured
prey from putrefaction in a humid and hot tropical environ-
ment. Unlike other species of spiders, tarantulas do not use
web-strategy to capture their prey, and they devour the prey
within minutes. Hence, the occurrence of such a protein with
reversible neurotoxic property in its venom possibly suggests
venom co-evolution within the Phyla. These toxin(s) in asso-
ciation with/without other components may act by unknown
mechanism(s) to bring down the basal metabolic rates of its
victims to a minimum level, causing a natural ‘refrigeration
e¡ect’. This e¡ect is most commonly utilized by other arthro-
pods, such as wasps and hornets, to store food for the survival
of its brood [33].
In summary, a novel peptide toxin has been puri¢ed and
characterized from the venom of Singapore tarantula C. vali-
dus. This insect-speci¢c toxin may be used as a tool for
understanding molecular mechanisms involved in reversible
paralysis with the possibility of providing a better insight
into the development of selective bio-insecticides. However,
further cellular and molecular studies are needed to under-
stand the mechanism(s) of reversible paralysis of crickets by
Cvtx-II.
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